Daniel
Middle Name
Y.
Wang, M.D.
Middle Name
Y.
Picture
Daniel
Middle Name
Y.
Wang, M.D.
Middle Name
Y.
Assistant Professor
Phone
Phone
Positions
- Assistant Professor
-
Medical Oncology
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States
Addresses
- McNair Campus (Clinic)
-
Dan L Duncan Comprehensive Cancer Center
7200 Cambridge St.
Houston, TX 77030
United States
Phone: (713) 798-3750
Fax: (713) 798-4020
Education
- BA from Rice University
- Houston, Texas United States
- MD from Baylor College of Medicine
- Houston, Texas United States
- Residency at Baylor College of Medicine
- Houston, Texas United States
- Clinical Fellowship at Vanderbilt University Medical Center
- Nashville, Tennessee United States
Certifications
- Medical Oncology
- ABIM
- Internal Medicine
- ABIM
Professional Interests
- Melanoma
- Non-melanoma skin cancers (Basal cell carcinoma, Squamous cell carcinoma, and Merkel cell carcinoma)
- Sarcoma
- Immune-related adverse events
Websites
Selected Publications
- Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV et al "Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement." JCI Insight. 2018 December 20; 3 (24): Pubmed PMID: 30568030
- Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM et al "Clinical characterization of colitis arising from anti-PD-1 based therapy." Oncoimmunology. 2018 October 31; 8 (1): Pubmed PMID: 30546965
- Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A et al "Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy." Cancer. 2018 December 6; : Pubmed PMID: 30521084
- Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F et al "Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis." JAMA Oncol. 2018 December 1; 4 (12): 1721-1728. Pubmed PMID: 30242316
- Johnson DB, Beckermann KE, Wang DY "Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease." Oncology (Williston Park). 2018 April 15; 32 (4): 190-4. Pubmed PMID: 29684232
- McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR et al "Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis." Lancet Oncol. 2018 March ; 19 (3): 310-322. Pubmed PMID: 29449192
- Wang DY, Johnson DB, Davis EJ "Toxicities Associated With PD-1/PD-L1 Blockade." Cancer J. 2018 January ; 24 (1): 36-40. Pubmed PMID: 29360726
- Wang DY, Ye F, Zhao S, Johnson DB "Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis." Oncoimmunology. 2017 July 5; 6 (10): Pubmed PMID: 29123955
- Wang DY, Johnson DB "When to consider alternatives to front-line immune therapies in metastatic melanoma." Melanoma Manag. 2017 May ; 4 (2): 71-74. Pubmed PMID: 30190906
- Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F et al "Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma." Cancer Immunol Res. 2017 May ; 5 (5): 357-362. Pubmed PMID: 28396509
- Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ "Cardiovascular Toxicities Associated with Cancer Immunotherapies." Curr Cardiol Rep. 2017 March ; 19 (3): 21. Pubmed PMID: 28220466
- Wang DY, Johnson DB "Advances in the development of intralesional therapies for melanoma." Melanoma Manag. 2016 December ; 3 (4): 259-266. Pubmed PMID: 30190897
- Wang DY, Sosman JA, Johnson DB "Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics." Oncology (Williston Park). 2015 December ; 29 (12): 1005-6. Pubmed PMID: 26680225
Log In to edit your profile
